Compare COHU & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHU | MESO |
|---|---|---|
| Founded | 1947 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 1994 | 2005 |
| Metric | COHU | MESO |
|---|---|---|
| Price | $49.86 | $15.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $74.63 | $37.00 |
| AVG Volume (30 Days) | ★ 1.1M | 260.7K |
| Earning Date | 10-28-2026 | 08-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | ★ $452,956,000.00 | N/A |
| Revenue This Year | $37.74 | $51.86 |
| Revenue Next Year | $33.35 | $63.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.74 | N/A |
| 52 Week Low | $21.10 | $11.89 |
| 52 Week High | $75.72 | $21.50 |
| Indicator | COHU | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 39.87 | 57.26 |
| Support Level | $49.06 | $13.77 |
| Resistance Level | $52.43 | $16.06 |
| Average True Range (ATR) | 3.78 | 0.45 |
| MACD | -0.80 | 0.31 |
| Stochastic Oscillator | 22.47 | 78.63 |
Cohu Inc is a supplier of semiconductor test and inspection handlers, micro-electro-mechanical system (MEMS) test modules, test contactors, and thermal sub-systems used by semiconductor manufacturers and test subcontractors. The company's products include Semiconductor ATE (Automated Test Equipment), Semiconductor Handlers, Interface Products such as test contactors, probe heads, and probe pins, Spares and Kits, Bare Board PCB Test Systems, and services. It has one reportable segment, Semiconductor Test and Inspection Equipment (Semiconductor Test & Inspection). Geographically, the company generates maximum revenue from the Philippines, followed by Taiwan, China, Malaysia, the United States, Singapore, and the Rest of the world.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.